Comparative Pharmacology
Head-to-head clinical analysis: ALLEGRA HIVES versus TRIPROLIDINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLEGRA HIVES versus TRIPROLIDINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
ALLEGRA HIVES vs TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.
Triprolidine is a first-generation antihistamine that competes with histamine for H1-receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a nasal decongestant via alpha-adrenergic receptor activation, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing antitussive effects by suppressing the cough center in the medulla.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
Each 5 mL oral solution contains triprolidine HCl 1.25 mg, pseudoephedrine HCl 30 mg, and codeine phosphate 10 mg. Adult dose: 10 mL (2 teaspoonfuls) every 4 to 6 hours, not to exceed 40 mL in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours). This supports once-daily dosing in most patients; however, in moderate to severe renal impairment, half-life may be prolonged (e.g., ~22 hours), necessitating dosing adjustment.
Triprolidine: 3-6 hours (increased in elderly). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine; up to 16 hours at pH 8). Codeine: 2.5-3.5 hours (terminal half-life; morphine metabolite ~2-3 hours).
Fexofenadine is primarily excreted unchanged in feces (80%) and urine (11%). The remainder undergoes minimal hepatic metabolism. Renal elimination accounts for about 11% of the dose.
Triprolidine: predominantly renal (85% as metabolites, <5% unchanged). Pseudoephedrine: renal (70-90% unchanged, dependent on urine pH). Codeine: renal (86% total, 5-15% unchanged, rest as conjugates and metabolites including morphine).
Category C
Category A/B
Antihistamine
Antihistamine